Katherine Wandersee

In the 2023 Donald Paty Lecture, speaker Darin Okuda presented novel MRI methods that might help determine whether MS lesions have potential for future remyelination.

The first results from a phase 2 study frexalimab (SAR441344; Sanofi), in relapsing multiple sclerosis have shown promise for the anti-CD40L antibody.

Although the CDC has declared the public health emergency for the COVID-19 pandemic over, patients with multiple sclerosis and other conditions are still in need of guidance.

Jennifer Graves, MD, PhD, presented data at the CMSC annual meeting suggesting that secondary progressive disease might be more age-related than previously realized.

Andrew Solomon, MD, discussed inherent biases affecting MS diagnosis and how advances in imaging may help curb diagnostic errors.